Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety…